![]() |
Name |
alpha-Vetispirene
|
Molecular Formula | C15H22 | |
IUPAC Name* |
(5S,6R)-6,10-dimethyl-3-prop-1-en-2-ylspiro[4.5]deca-3,9-diene
|
|
SMILES |
C[C@@H]1CCC=C([C@@]12CCC(=C2)C(=C)C)C
|
|
InChI |
InChI=1S/C15H22/c1-11(2)14-8-9-15(10-14)12(3)6-5-7-13(15)4/h6,10,13H,1,5,7-9H2,2-4H3/t13-,15+/m1/s1
|
|
InChIKey |
KEVTZKPBXQTBSV-HIFRSBDPSA-N
|
|
Synonyms |
alpha-Vetispirene; 28908-28-3
|
|
CAS | NA | |
PubChem CID | 11298626 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 202.33 | ALogp: | 4.8 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.519 |
Caco-2 Permeability: | -4.477 | MDCK Permeability: | 0.00001330 |
Pgp-inhibitor: | 0.015 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.126 |
30% Bioavailability (F30%): | 0.214 |
Blood-Brain-Barrier Penetration (BBB): | 0.057 | Plasma Protein Binding (PPB): | 94.10% |
Volume Distribution (VD): | 2.23 | Fu: | 5.54% |
CYP1A2-inhibitor: | 0.956 | CYP1A2-substrate: | 0.465 |
CYP2C19-inhibitor: | 0.838 | CYP2C19-substrate: | 0.831 |
CYP2C9-inhibitor: | 0.549 | CYP2C9-substrate: | 0.503 |
CYP2D6-inhibitor: | 0.755 | CYP2D6-substrate: | 0.176 |
CYP3A4-inhibitor: | 0.532 | CYP3A4-substrate: | 0.345 |
Clearance (CL): | 14.089 | Half-life (T1/2): | 0.236 |
hERG Blockers: | 0.157 | Human Hepatotoxicity (H-HT): | 0.58 |
Drug-inuced Liver Injury (DILI): | 0.029 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.123 | Maximum Recommended Daily Dose: | 0.543 |
Skin Sensitization: | 0.956 | Carcinogencity: | 0.339 |
Eye Corrosion: | 0.898 | Eye Irritation: | 0.925 |
Respiratory Toxicity: | 0.867 |